Stevanato Group S.p.A. (STVN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Stevanato Group S.p.A. (STVN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

21.57

-0.35 (-1.60%)

At close: Jan 14, 2025, 3:59 PM

21.65

0.37%

After-hours Jan 14, 2025, 07:00 PM EST

undefined% (undefined)

Bid	n/a
Market Cap	5.88B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.42
PE Ratio (ttm)	51.36
Forward PE	n/a
Analyst	Buy

Ask	26
Volume	290,656
Avg. Volume (20D)	469,227
Open	21.96
Previous Close	21.92
Day's Range	21.15 - 22.23
52-Week Range	16.56 - 34.73
Beta	undefined

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, I...

[Show more]

Industry Medical - Instruments & Supplies

Sector Healthcare

IPO Date Jul 16, 2021

Employees 5,635

Stock Exchange NYSE

Ticker Symbol STVN

Website https://www.stevanatogroup.com

Analyst Forecast

According to 6 analyst ratings, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 20.54% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Stevanato Group S.p.A. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of $352.00M, reflecting a 2.00% YoY growth and earnings per share of 0.2, making a 3.09% increase YoY.

Why Price Moved

1 month ago · Source

+3.74%

Stevanto Group shares are trading higher after Wol... Unlock content with Pro Subscription

5 months ago · Source

+5.75%

Stevanato Group shares are trading higher after the company reported better-than-expected Q2 revenue results.

News

6 days ago · zacks.com

UTHR vs. STVN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to...

1 week ago · businesswire.com

Stevanato Group to Present at Upcoming Investor Conference

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences...

2 months ago · seekingalpha.com

Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement

Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin imp...

2 months ago · businesswire.com

Stevanato Group to Present at Upcoming Investor Conferences

2 months ago · zacks.com

CPRX vs. STVN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for tho...

2 months ago · seekingalpha.com

Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Transcript

Stevanato Group S.p.A. (NYSE:STVN ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairma...

2 months ago · zacks.com

Stevanato Group (STVN) Q3 Earnings Match Estimates

Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.16 per share a year ago.

2 months ago · businesswire.com

Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology a...

2 months ago · zacks.com

Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

CPRX or STVN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investor...